Wearable Biosensors to Evaluate Recurrent Opioid Toxicity After Naloxone Administration: A Hilbert Transform Approach by Chintha, Keerthi Kumar. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
UMass Center for Clinical and Translational 
Science Supported Publications 
University of Massachusetts Center for Clinical 
and Translational Science 
2018-01-03 
Wearable Biosensors to Evaluate Recurrent Opioid Toxicity After 
Naloxone Administration: A Hilbert Transform Approach 
Keerthi Kumar. Chintha 
University of Texas at Tyler 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/umccts_pubs 
 Part of the Biomedical Devices and Instrumentation Commons, Health Information Technology 
Commons, Investigative Techniques Commons, Medical Toxicology Commons, Substance Abuse and 
Addiction Commons, and the Translational Medical Research Commons 
Repository Citation 
Chintha KK, Indic P, Chapman B, Boyer EW, Carreiro S. (2018). Wearable Biosensors to Evaluate Recurrent 
Opioid Toxicity After Naloxone Administration: A Hilbert Transform Approach. UMass Center for Clinical 
and Translational Science Supported Publications. Retrieved from https://escholarship.umassmed.edu/
umccts_pubs/130 
Creative Commons License 
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License. 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Center for 
Clinical and Translational Science Supported Publications by an authorized administrator of eScholarship@UMMS. 
For more information, please contact Lisa.Palmer@umassmed.edu. 
Wearable Biosensors to Evaluate Recurrent Opioid Toxicity After Naloxone 
Administration:  A Hilbert Transform Approach 
 
Keerthi Kumar Chintha 
Department of Electrical 
Engineering 
University of Texas at Tyler, Tyler, 
TX 
KChintha@patriots.uttyler.edu 
Premananda Indic 
Department of Electrical 
Engineering 
University of Texas at Tyler, Tyler, 
TX 
pindic@uttyler.edu 
Brittany Chapman 
Department of Emergency Medicine 
Division of Medical Toxicology 
University of Massachusetts 
Medical School, Worcester, MA 
Brittany.Chapman@umassmed.edu 
Edward W Boyer 
Department of Emergency Medicine 
Division of Medical Toxicology 
Brigham and Women’s Hospital, 
Boston, MA 
Eboyer@bwh.harvard.edu 
Stephanie Carreiro 
Department of Emergency Medicine 
Division of Medical Toxicology 
University of Massachusetts 
Medical School, Worcester, MA 
stephanie.carreiro@umassmemorial.
org 
 
Abstract 
 Opioid abuse is a rapidly escalating problem in 
the United States.  Effective opioid reversal is 
achieved with the antidote naloxone, but often does not 
last as long as the offending opioid, necessitating in-
hospital observation.   Continuous physiologic 
monitoring using wearable biosensors represents a 
potential option to extend monitoring capability 
outside the clinical setting across the spectrum of 
opioid abuse including post- naloxone administration. 
The present study aims to identify the physiologic 
change that marks the cessation of naloxone’s effect.  
Eleven participants were recruited in the Emergency 
Department after naloxone administration for an 
opioid overdose and continuously monitored using a 
wearable biosensor measuring heart rate, 
temperature, electrodermal activity and 
accelerometry.    Hilbert transform was used to 
evaluate a 90- minute post naloxone time point.  
Physiologic changes were consistent with the onset of 
opioid drug effect across parameters, but only 
changes in heart rate and skin temperature research 
statistical significance.   
 
1. Introduction  
 
 The United States is currently in the midst of an 
opioid epidemic, with over thirty thousand deaths 
attributed to opioids in 2015 alone [1]  Unlike many 
other dangerous drugs, an effective antidote, naloxone, 
is widely available for opioid overdose.  Naloxone 
blocks opioid receptors, to reverse the toxic effects of 
opioids (such as respiratory depression) when 
administered after an overdose [2]. Naloxone is widely 
available to both medical personnel and to the general 
public.  With a duration of effect of naloxone is 30-90 
minutes [2], the antidote may not last as long as the 
opioid that initially caused the overdose[3][4].  
Consequently, patients who receive naloxone for 
overdose still require transport to a hospital for 
observation to ensure opioid toxicity will not reoccur 
after the antidote is no longer in effect[5]. Many 
individuals nonetheless refuse transport to (or 
observation in) a hospital after they receive naloxone, 
and are thus at risk for devastating consequences if 
opioid toxicity re-occurs in the absence of medical 
attention. 
 
 Wearable sensors have significant potential for 
use across the spectrum of opioid use disorders[6]. 
Using changes in continuously monitored physiologic 
parameters,  they have already been shown to identify 
drug use (including opioid use) as it occurs in real time 
[7]-[9]. In the context of overdose and naloxone 
treatment, continuous biosensing may provide a way 
to decrease hospital observation time and possibly 
allow for monitoring outside of the hospital altogether.  
As a first step, we aim to identify the physiologic 
profile associated with the cessation of naloxone 
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activity (which heralds a time of significant risk for 
recurrence of opioid toxicity).   We hypothesize that 
as the naloxone loses effect, a participant’s biometric 
profile will shift from one consistent with opioid 
withdrawal to one consistent with opioid intoxication.  
Since the data are collected in real time in a natural 
setting (as opposed to a controlled laboratory), the 
obtained data are highly non-stationary. Therefore, we 
employed a Hilbert transform approach to extract 
relevant features from the data.  
 
2. Methods 
 
 This study was approved by the Institutional 
Review Board at the corresponding author’s 
institution. 
 
2.1. Hardware 
 
 The study was conducted using the E4 wrist-
mounted biosensor (Empatica, Milan, Italy, Figure 1), 
which continuously measures skin temperature, three 
dimensional accelerometry, electrodermal activity 
(EDA) and heart rate. The accelerometer data was 
acquired at a sampling rate of 32Hz, heart rate at 1Hz, 
EDA and temperature at 4Hz. The collected data was 
stored on the devices’ onboard memory, uploaded to a 
secure, HIPAA-compliant server using the Empatica 
Manager application, and then downloaded in comma 
separated value (csv) format using the Empatica 
Connect application.  
 
2.2. Participants 
 
 Inclusion criteria for participants were as follows: 
1) Emergency Department (ED) patients, 2) 18 years 
of age or older, 3) known or suspected diagnosis of 
opioid toxicity, and 4) treatment with the opioid 
antagonist naloxone by Emergency Medical Service 
(EMS) providers or by ED staff. Individuals were 
excluded if they: 1) use anticholinergic medications, 
2) received naloxone by non-medical personnel 
(bystanders) only, 3) had known concomitant non-
opioid ingestions at the time of presentation, 4) had an 
amputation of the non-dominant arm, or 5) had 
significant limitation of range of motion (i.e. acute 
orthopedic injuries). 
 
2.3. Study Protocol 
 
 The E4 was placed on the participant’s non-
dominant wrist upon arrival to the ED, and continuous 
acquisition of biometric data occurred for the duration 
of study participation. Monitoring began immediately, 
and continued until one of the following predefined 
endpoints were reached: 1) discharge/transfer from the 
ED, 2) placement of participant on continuous 
naloxone infusion, or 3) decision by the participant to 
withdraw from the study. 
 
 Non-biometric data collected by self-report from 
the participant and verified by the electronic medical 
record (EMR) included: medical history, home 
medication lists, substance abuse history, social 
history and circumstances surrounding the current 
overdose event. Additional non-biometric data 
collected from the EMR included:  demographic 
information, vital signs, medication administrations 
from the ED visit, and the timing, dose and route of 
naloxone administration on the day of enrollment. 
Clinical assessments were performed once per hour 
while the participant was enrolled to document 
presence of either opioid intoxication or opioid 
withdrawal.  
 
 Participant self-reported history of ingestion, as 
well as clinical evaluation by both the treating 
Emergency Physician and a Medical Toxicologist 
were used to classify each participant into three 
categories: 1) opioid toxicity without reoccurrence, 2) 
opioid toxicity with reoccurrence (requiring 
subsequent doses of naloxone), and 3) non-
opioid/polysubstance intoxication.  Only those in 
category 1 (opioid toxicity without re-occurrence) 
were included for this analysis. 
 
 
2.4. Data Analysis 
 
 As described previously [7], to understand the 
rapid fluctuations and heterogeneity inherent in the 
measurement of locomotion at three different axes, we 
estimated the amplitude of the fluctuations using a 
Hilbert transform method[10]. We applied Hilbert 
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transform to the locomotion data, 𝑑 𝑡 ,	 at each of the 
axes, XYZ, to obtain the analytic signal 
 
where 𝑖 represents the complex variable and  
 
 The amplitude, 𝑎 𝑡 , is estimated as the absolute 
value of 𝐴(𝑡) and this procedure is applied to the data 
collected for each of the axes to obtain corresponding 
amplitudes. To study the fluctuations in the amplitude, 
we plotted the distribution of amplitudes and  
characterized the distribution with an appropriate 
distribution function. Since the obtained amplitude is 
from non-stationary data, we found the characterizing 
parameter using a running window approach with 5-
minute length durations, with 4 minutes overlapping.  
 
 Naloxone has a duration of action up to 90 
minutes from the time it is administered. To 
understand the biometric effects of this antidote, we 
obtained administration times and estimated the time 
its effects were expected to wear off (90 minutes after 
administration). For this analysis, 90 minutes post-
naloxone administration was referred to as time N90. 
We calculated the characterizing parameters of the 
distribution 30 minutes before and 30 minutes after 
this time N90 using the running window approach.   
 
 We studied whether characterizing parameters of 
the distribution show any significant effect of 
naloxone before and after time N90.  We also studied 
whether the fluctuations in other signals, such as heart 
rate, temperature and EDA also shows any significant 
difference before and after time N90.  
 
3. Results  
 
3.1 Demographic Data 
 
 Thirty-eight individuals were approached 
regarding study participation. A total of 18 were 
excluded due to polysubstance intoxication (N=10), 
bystander only/unconfirmed naloxone administration 
(N=5), or unwillingness to participate (N=3). Twenty 
participants enrolled and were monitored: 3 were  
classified as opioid toxicity with recurrence (requiring 
additional doses of naloxone) and 17 were classified 
as opioid toxicity with no recurrence. Eleven of the 17 
non-recurrent participants were included in analysis: 1 
was excluded to a device failure and 5 had insufficient 
volume of data for analysis.  All included participants 
reported heroin as the opioid responsible for the 
overdose.  Demographic data is described in Table 1. 
 
3.2 Biometric Data 
 
  
 The data obtained in csv format were imported to 
MATLAB version R2016b, which was used for all 
analyses (Mathworks, Natick, MA). Figure 2 is a 
representative example of the accelerometer data in 
three of the axes, XYZ, for a single participant. 
 
 We determined time N90 (marked as time = 0 and 
a green vertical line) based on documented time of 
naloxone administration and applied Hilbert transform 
to obtain the amplitude 𝑎 𝑡  for each of the axes 
separately. Prior to applying Hilbert transform, we 
subtracted the mean from the raw data.  Figure 3 
represents the amplitude 𝑎(𝑡) calculated for each of 
the axis from a 5-minute segment before (yellow 
Table 1:  Demographic data for all participants 
  N=11 
Age (mean, range) 36 (23, 50) 
Race   
      White  10 
      Other 1 
Ethnicity   
      Hispanic/Latino 2 
      Non-Hispanic/Latino 9 
Gender   
      Male 9 
      Female 2 
Total dose of naloxone in mg (mean) 3.5 (2, 6) 
Duration of biosensor recording in hours 
(mean, range) 
2.6 (0.83, 
6.35) 
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shading on Figure 2) and after (green shading on 
Figure 2).  
 
Similar to our previous work, we found that the 
amplitude follows a long tail distribution and we used 
a Gamma probability density function (pdf) to 
characterize the distribution. Thus, given the 
amplitude 𝑎(𝑡), the Gamma pdf is obtained as  
 
 
 Where 𝛼 and 𝛽 represent the shape and scale 
parameters respectively. Since these characterizing 
parameters are estimated for each of the axis XYZ, we 
obtained a total of six measures (two measures, shape 
and scale, for each of the three axes).  Figure 4 
represents the distribution function fit of the 
amplitudes represented in Figure 3.  
 
 To get a comprehensive view of the changes in 
biometric data, we explored whether we can define a 
single parameter to differentiate the features in the 
biometric data before and after. In a six dimension, 
hypothetical space with each of the above-mentioned 
measures representing the axis of this space, we 
defined a measure equivalent to distance as    
 
 
We also calculated the mean value of heart rate, EDA 
and temperature using the same sliding window 
approach.        
 
 
Figure 5 represents time evolution of  𝐷-, heart rate, 
EDA and temperature calculated for each 5-minute 
sliding window with an overlap of 4 minutes for the 
participant 10. 
 We investigated whether the fluctuations 
observed in these measures are significantly different 
between before and after in each of the 11 participants. 
Table 2 shows such analysis. In seven of the 
participants, we found that some of the measures are 
significantly different between before and after. 
However, significant differences in all of the measures 
were only found in three of the participants.  
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 Figure 6 represents the overall mean of 𝐷- , heart 
rate, EDA and temperature along with their respective 
standard error. We found that in group comparison, 𝐷- 
is not significant (P=0.11), heart rate is significant 
(P=0.007), EDA is not significant (P=0.22) and 
temperature is significant (P=0.01). This mixed result 
is not surprising due to inter participant variability that 
is often observed in their response.  
 
4.Discussion 
 
 Our data demonstrates a significant shift in 
physiology detected by a wearable biosensor as the 
opioid antagonist naloxone wears off. The profile 
change is physiologically similar to that seen with de 
novo opioid use in prior literature[7].  This makes 
sense from a physiologic standpoint since the original  
opioid agonist that caused the overdose in these  
patients would resume their physiologic effect once 
naloxone (the antagonist) wears off.  This is clinically 
significant for a number of reasons.  First, it can allow 
for remote monitoring after naloxone use, and identify 
risk of reoccurrence of opioid toxicity.  Second, this 
profile should be physiologically identical to the 
profile for the onset of opioid use/overdose and thus  
 
 
can be used identify de novo overdoses and trigger a 
warning or a call for help. 
The methodology described also provides new 
insight toward the application of wearable sensors in 
opioid abuse. Using a traditional Hilbert transform 
method, we derived the amplitude from a highly non-
stationary data. The interesting aspect of the analysis 
of locomotor data is the long tail distribution observed 
in the amplitude distribution. Such distributions 
represent an organization in the locomotor activity due 
to nonlinear interactions, and may provide clues to the 
detection of opioid use physiology. 
 
5. Strengths and Limitations  
 
 Our study was conducted in a population of 
recreational opioid users in a natural setting; this made 
the data less precise than if opioids were given in a 
controlled laboratory setting, but this increases the 
generalizability of our findings to the real world. 
 Because participants were recruited upon arrival 
to the hospital, biosensor data was not available from 
the time of naloxone administration (in the pre-
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Figure 6: Mean and standard error of   𝐷-, HR, EDA and Temperature values 
obtained from all subjects (N=11) before and after N90 
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hospital setting) to the time of hospital arrival.  
Transport time was variable, depending on the 
participants’ original location, so several participants 
were excluded from the analysis due to insufficient 
volume of data.  Also, as described in the recruitment 
setting, many participants screened out before 
enrollment or had to be excluded later due to 
concomitant ingestion of non-opioid drugs; 
physiologic influence from other substances would 
have inevitably confounded the data.   
 In this work, we had only a few number of 
participants to derive the features relevant to the effect 
of naloxone wearing off from the system. Although we 
could differentiate the effect of the antidote wearing 
off in the individual by observing the fluctuations of 
the features that we derived, as a group, we found only 
two features (heart rate and temperature) significantly 
different between before and after conditions. In this 
work, we employed Gamma distribution to 
characterize the long tail distribution, however we 
have not explored whether any other distribution will 
be a better fit than Gamma distribution.  
 
6. Conclusions 
 
 A Hilbert transform analytic method can be 
applied to wearable biosensors to detect significant 
changes in physiology as the effect of the opioid 
antagonist naloxone wears off.  This is a first step in 
the use of wearable sensors to remotely monitor 
patients with opioid toxicity.   Potential future 
applications are wide, and could allow for shorter ED 
observation periods or possible even observation 
outside of the hospital after naloxone is administered 
for an opioid overdose.  These findings also have 
implications beyond individuals who have received 
naloxone.  The ability to detect opioid toxicity before 
it is apparent clinically could provide a means for early 
identification (both in and out of the hospital setting) 
and thus opportunities for intervention to dramatically 
decrease morbidity and mortality from opioid 
overdoses.  Additional research is needed to identify 
other events across the spectrum of illness (opioid 
overdose and recurrence of toxicity), to capture 
naloxone administration, and to trial wearables in 
natural settings of opioids. 
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